Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | PREP | P48147 | 10/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6051964 | 1.00 | ACE (0.55) | ACEPREPMEN1TSHRHTT | |
| SCHEMBL11220344 | 0.93 | ACE (0.54) | ACEPREPMEN1TSHRHTT | |
| SCHEMBL6052009 | 0.86 | ACE (0.53) | ACEPREPDPP4DPP8DPP7 | |
| SCHEMBL11381314 | 0.85 | ACE (0.54) | ACEPREPDPP4DPP8DPP7 | |
| SCHEMBL10940644 | 0.83 | ACE (0.53) | ACEPREPDPP4DPP8DPP7 | |
| SCHEMBL20718946 | 0.82 | ACE (0.53) | ACEPREPKMT2ADPP4DPP8 | |
| SCHEMBL11392768 | 0.81 | ACE (0.59) | ACEPREP | |
| SCHEMBL31590738 | 0.81 | ACE (0.51) | ACEPREPKMT2ADPP4DPP8 | |
| SCHEMBL9362241 | 0.81 | ACE (0.51) | ACEPREP | |
| SCHEMBL7352024 | 0.81 | ACE (0.51) | ACEPREPKMT2ADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ACE 1083/4885PREP 1510/4885MEN1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.